Sun Pharma mulls 10% of income for R&D
By agencies   |   Thursday, 02 February 2006, 20:30 IST
Printer Print Email Email
MUMBAI: With the accent continuing to be on research, Mumbai-based drug company Sun Pharmaceutical Industries Ltd looks to peg its spending at over 10 percent of sales, company’s Chairman and Managing Director, Dilip Shanghvi said. “Investments in research and development (R&D) continue to increase as we create intellectual property (IP) for the long-term,” he said. The cumulative number of abbreviated new drug applications (ANDA) between Sun Pharma and its U.S.-based subsidiary, Caraco Pharma, stands at 38, till December 2005. Shanghvi said, “This includes a mix of products, para 3s, some para 4s and some difficult dosage forms. So, we are building for a dependable revenue stream as well as a likely upside.” Outlining the progress of Sun Pharma’s innovative products, he said that Sun's new chemical entity has completed Phase I study and the company expected to open the investigative new drug (IND) procedures in the next couple of months. The company are also on track to file IND for 2 NDDS (new drug delivery systems) in the next few months, most likely one next quarter and one more after that," shanghvi said, adding that specifics would be divulged only after trials clear Phase II. The company has seen a string of acquisitions in the U.S. and Europe last year. At present Sun is sitting on large amounts of cash and a large U.S. acquisition is still on the cards.

siliconindia